NCT07651124Recruiting
To Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
A Clinical Trial to Evaluate the Safety of Autologous Tumor-infiltrating Lymphocytes(TILs) for the Treatment of Recurrent Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 16 Jun 2026
Brief summary (registry, in English)
The objective of this clinical trial is to evaluate the safety of autologous tumor-infiltrating lymphocytes and to investigate their efficacy in recurrent ovarian cancer. Participants undergo the following process: There must be a cancerous lesion available for biopsy or surgery, and enhanced tumor-infiltrating lymphocytes are cultured from ovarian cancer tissue collected from the subject. These are processed into human cells for administration and injected into the subject.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 6 (estimated)
- First submitted
- 10 Jun 2026
- Start date
- 1 Apr 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Yong Wha Moon
- Diseases
- Ovarian cancer
- NCT number
- NCT07651124
What you commit to
- Study type: Interventional
- Planned participants: 6
- From 1 Apr 2025 to the primary completion date, 31 Dec 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patient with immunodeficiency or autoimmune diseases that may be exacerbated by immunotherapy
Other
- Patient deemed unsuitable by the principal investigator
Who the study is looking for
- Recurrent ovarian cancer
- There is a cancerous lesion that can be removed by biopsy or surgery.
Age in the registry: 20 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bundang CHA Medical Center Coordinator of this site? Confirm its status | Gyeonggi-do | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.